PEG-l-asparaginase, commonly called PEG, is a cytotoxin, a drug that specifically targets and starves cancerous cells. A variant of asparaginase, PEG has become a core part of leukemia treatment protocols.
PEG is typically administered intravenuously over an hour or two. Some patients may have severe reactions to it and may need to premedicate with drugs to ease the reaction symptoms, or may be unable to handle it at all. In cases where the patient cannot proceed with PEG, Erwinaze will typically be tried instead.